Liposomal formulation opens new therapeutic possibilities for a wide range of active substances. By tailoring nanocarriers to the specific properties of both the drug and the target tissue, InnoMedica can enable efficient delivery to the intended site of action. The technology platform is suitable for clinically established compounds as well as emerging therapeutic modalities, such as RNA- and protein-based agents, and forms the foundation of a growing pipeline.
The treatment of Parkinson’s disease is InnoMedica’s central development program. Through the nanocarrier, the active substance GM1 is delivered to the brain, where it exerts its neuroprotective and neuroregenerative effects. Parkinson’s treatment is the primary focus of clinical development up to and including Phase II. Given GM1’s broad biological mechanism of action, other neurodegenerative diseases, such as amyotrophic lateral sclerosis (ALS), may also benefit from a GM1-based therapy.
The novel chemotherapy for breast cancer utilizes a liposomal formulation of doxorubicin to reduce the typical side effects associated with the treatment. In the next clinical phase, the rare tumor type soft tissue sarcoma (STS) will be further investigated, as there is a significant need for better and more tolerable treatment options.
In addition to the lead programs, InnoMedica is developing further therapeutic approaches that demonstrate the potential of nanotechnology for indication expansion and new clinical applications. TLTrace is an intraoperative tumor-labeling product designed to enable more precise identification and removal of tumor tissue during surgery. Furthermore, InnoMedica is pursuing TLTaxel, a liposomal reformulation of the established chemotherapy agent docetaxel, with the aim of improving efficacy while enhancing tolerability. These projects meaningfully complement the pipeline and demonstrate the flexibility of the platform for future applications.
Research
Preclinical
Clinical
Thanks to the unique composition of the nanocarrier for InnoMedica's neurology product, the active ingredient GM1 ganglioside that is integrated into the membrane can cross the blood-brain barrier and unfold its neuroprotective and neuroregenerative effect in the brain. GM1 ganglioside is an important component of nerve cells and plays a central role in neuronal development, information transmission and storage, in repair mechanisms and in the release of neurotrophins (messenger substances that are essential for the survival and regeneration of nerve cells). As InnoMedica's nanocarrier crosses the blood-brain barrier, the brain is supplied with more GM1 to protect the nerve cells. As it is an endogenous substance, it is also well tolerated.
The nanocarrier of InnoMedica's oncology product transports the already approved, highly effective active ingredient doxorubicin and is designed to prevent serious, sometimes irreversible side effects of this chemotherapy. The intelligent surface coating of the liposomal nanoparticle ensures minimal interaction of the active ingredient with healthy tissue. The longer blood circulation time protects the excretory organs as they have more time for the degradation process. As the liposomal nanocarrier of the preparation is particularly small, targeted penetration of the tumor tissue and thus a high level of drug accumulation in the tumor is ensured.
